Latest News and Press Releases
Want to stay updated on the latest news?
-
BRISBANE, Calif., Feb. 24, 2020 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK), today announced that Taylor Harris, Chief Financial Officer, will present at the 40th Annual Cowen Health Care...
-
BRISBANE, Calif., Feb. 20, 2020 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK), today announced that it will report fourth quarter and full year 2019 financial and operating results on Thursday,...
-
SOUTH SAN FRANCISCO, Calif., Jan. 06, 2020 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK), today announced that Tassos Gianakakos, Chief Executive Officer, will present at the 38th Annual J.P....
-
SOUTH SAN FRANCISCO, Calif., Nov. 27, 2019 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK), today announced that Tassos Gianakakos, Chief Executive Officer, will participate in a fireside chat at...
-
MyoKardia Announces Positive Topline Data from its Phase 2 MAVERICK-HCM Clinical Trial of Mavacamten
Achieved Primary Study Objective of Safety and Tolerability in Patients with Non-obstructive HCM Significant Reductions in Biomarkers of Cardiac Stress Observed in Patients on Treatment vs. Placebo...
-
Mavacamten’s Safety and Efficacy Profile in the PIONEER Study Maintained Through One Year in Open-Label Extension Study of 12 Patients with Symptomatic, Obstructive HCM Evidence Suggests Mavacamten’s...
-
SOUTH SAN FRANCISCO, Calif., Nov. 06, 2019 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK), today announced that Tassos Gianakakos, Chief Executive Officer, will participate in a fireside chat at...
-
SOUTH SAN FRANCISCO, Calif., Nov. 04, 2019 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK), today reported financial results for the quarter ended September 30, 2019. “As we look across the...
-
SOUTH SAN FRANCISCO, Calif., Nov. 04, 2019 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK), today announced the presentation of several abstracts at the upcoming American Heart Association (AHA)...
-
Interim Data Demonstrated Favorable Safety and Activity Profile in Phase 2a Multiple-Ascending Dose Study Phase 2 Clinical Trial in Targeted Segment of Genetic DCM to Initiate in 1H 2020 SOUTH SAN...